1 Min Read
FRANKFURT, March 13 (Reuters) - Bayer AG : * Says starts phase iiib study with riociguat in pah patients who had
insufficient response to pde-5 inhibitors
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.